Neoadjuváns szisztémás terápia emlorákban

Translated title of the contribution: Neoadjuvant systemic therapy in breast cancer

Z. Kahán, Aliz Nikolényi, Gabriella Uhercsák, L. Thurzó

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neoadjuvant (preoperative) systemic therapy is a good possibility for the treatment of symptomatic breast cancers of the locoregional stage. Chemotherapy or hormone therapy chosen according to the characteristics of the primary tumor, result in the regression of the tumor in the majority of the cases, favoring breast conserving surgery thereafter. The long-term effects of neoadjuvant systemic therapy are equivalent to that of adjuvant therapy, and the in vivo observed efficiency of the treatment reflects prognosis. Finally, systemic therapy introduced prior to surgery is not delayed by the possible adverse effects of the surgery. Detailed examination of the tumor and the patient is mandatory before starting systemic therapy. Besides breast imaging and histological examinations, staging is necessary. Pathological characterization of the tumor will enhance treatment choice based on the features of chemo- or hormone-sensitivity. For the treatment of chemosensitive tumors, taxane- and anthracycline-based polychemotherapy is the most efficacous. Data on neoadjuvant hormone therapy have been provided by studies on postmenopausal patients. Since the aromatase inhibitors are more efficient than tamoxifen, their use is the first option in this patient population. Among the molecular targeted agents, trastuzumab combined with chemotherapy produces extending therapeutic response rate. Following the completion of the neoadjuvant systemic therapy, breast imaging is required once more before performing breast and lymph node surgery. Postoperative radiotherapy is generally needed. The use of a common language and professional guidelines by the members of the multidisciplinary breast team is a condition for neoadjuvant systemic therapy.

Original languageHungarian
Pages (from-to)65-71
Number of pages7
JournalOrvosi Hetilap
Volume150
Issue number2
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Breast
Therapeutics
Hormones
Neoplasms
Drug Therapy
Aromatase Inhibitors
Segmental Mastectomy
Anthracyclines
Tamoxifen
Combination Drug Therapy
Language
Radiotherapy
Lymph Nodes
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neoadjuváns szisztémás terápia emlorákban. / Kahán, Z.; Nikolényi, Aliz; Uhercsák, Gabriella; Thurzó, L.

In: Orvosi Hetilap, Vol. 150, No. 2, 01.01.2009, p. 65-71.

Research output: Contribution to journalArticle

Kahán, Z. ; Nikolényi, Aliz ; Uhercsák, Gabriella ; Thurzó, L. / Neoadjuváns szisztémás terápia emlorákban. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 2. pp. 65-71.
@article{e1fc8989059442da9e649d69e8ec6e63,
title = "Neoadjuv{\'a}ns sziszt{\'e}m{\'a}s ter{\'a}pia emlor{\'a}kban",
abstract = "Neoadjuvant (preoperative) systemic therapy is a good possibility for the treatment of symptomatic breast cancers of the locoregional stage. Chemotherapy or hormone therapy chosen according to the characteristics of the primary tumor, result in the regression of the tumor in the majority of the cases, favoring breast conserving surgery thereafter. The long-term effects of neoadjuvant systemic therapy are equivalent to that of adjuvant therapy, and the in vivo observed efficiency of the treatment reflects prognosis. Finally, systemic therapy introduced prior to surgery is not delayed by the possible adverse effects of the surgery. Detailed examination of the tumor and the patient is mandatory before starting systemic therapy. Besides breast imaging and histological examinations, staging is necessary. Pathological characterization of the tumor will enhance treatment choice based on the features of chemo- or hormone-sensitivity. For the treatment of chemosensitive tumors, taxane- and anthracycline-based polychemotherapy is the most efficacous. Data on neoadjuvant hormone therapy have been provided by studies on postmenopausal patients. Since the aromatase inhibitors are more efficient than tamoxifen, their use is the first option in this patient population. Among the molecular targeted agents, trastuzumab combined with chemotherapy produces extending therapeutic response rate. Following the completion of the neoadjuvant systemic therapy, breast imaging is required once more before performing breast and lymph node surgery. Postoperative radiotherapy is generally needed. The use of a common language and professional guidelines by the members of the multidisciplinary breast team is a condition for neoadjuvant systemic therapy.",
keywords = "Breast cancer, Neoadjuvant chemotherapy, Neoadjuvant hormone therapy, Neoadjuvant systemic therapy, Predictive factors",
author = "Z. Kah{\'a}n and Aliz Nikol{\'e}nyi and Gabriella Uhercs{\'a}k and L. Thurz{\'o}",
year = "2009",
month = "1",
day = "1",
doi = "10.1556/OH.2009.28536",
language = "Hungarian",
volume = "150",
pages = "65--71",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Neoadjuváns szisztémás terápia emlorákban

AU - Kahán, Z.

AU - Nikolényi, Aliz

AU - Uhercsák, Gabriella

AU - Thurzó, L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Neoadjuvant (preoperative) systemic therapy is a good possibility for the treatment of symptomatic breast cancers of the locoregional stage. Chemotherapy or hormone therapy chosen according to the characteristics of the primary tumor, result in the regression of the tumor in the majority of the cases, favoring breast conserving surgery thereafter. The long-term effects of neoadjuvant systemic therapy are equivalent to that of adjuvant therapy, and the in vivo observed efficiency of the treatment reflects prognosis. Finally, systemic therapy introduced prior to surgery is not delayed by the possible adverse effects of the surgery. Detailed examination of the tumor and the patient is mandatory before starting systemic therapy. Besides breast imaging and histological examinations, staging is necessary. Pathological characterization of the tumor will enhance treatment choice based on the features of chemo- or hormone-sensitivity. For the treatment of chemosensitive tumors, taxane- and anthracycline-based polychemotherapy is the most efficacous. Data on neoadjuvant hormone therapy have been provided by studies on postmenopausal patients. Since the aromatase inhibitors are more efficient than tamoxifen, their use is the first option in this patient population. Among the molecular targeted agents, trastuzumab combined with chemotherapy produces extending therapeutic response rate. Following the completion of the neoadjuvant systemic therapy, breast imaging is required once more before performing breast and lymph node surgery. Postoperative radiotherapy is generally needed. The use of a common language and professional guidelines by the members of the multidisciplinary breast team is a condition for neoadjuvant systemic therapy.

AB - Neoadjuvant (preoperative) systemic therapy is a good possibility for the treatment of symptomatic breast cancers of the locoregional stage. Chemotherapy or hormone therapy chosen according to the characteristics of the primary tumor, result in the regression of the tumor in the majority of the cases, favoring breast conserving surgery thereafter. The long-term effects of neoadjuvant systemic therapy are equivalent to that of adjuvant therapy, and the in vivo observed efficiency of the treatment reflects prognosis. Finally, systemic therapy introduced prior to surgery is not delayed by the possible adverse effects of the surgery. Detailed examination of the tumor and the patient is mandatory before starting systemic therapy. Besides breast imaging and histological examinations, staging is necessary. Pathological characterization of the tumor will enhance treatment choice based on the features of chemo- or hormone-sensitivity. For the treatment of chemosensitive tumors, taxane- and anthracycline-based polychemotherapy is the most efficacous. Data on neoadjuvant hormone therapy have been provided by studies on postmenopausal patients. Since the aromatase inhibitors are more efficient than tamoxifen, their use is the first option in this patient population. Among the molecular targeted agents, trastuzumab combined with chemotherapy produces extending therapeutic response rate. Following the completion of the neoadjuvant systemic therapy, breast imaging is required once more before performing breast and lymph node surgery. Postoperative radiotherapy is generally needed. The use of a common language and professional guidelines by the members of the multidisciplinary breast team is a condition for neoadjuvant systemic therapy.

KW - Breast cancer

KW - Neoadjuvant chemotherapy

KW - Neoadjuvant hormone therapy

KW - Neoadjuvant systemic therapy

KW - Predictive factors

UR - http://www.scopus.com/inward/record.url?scp=60749122412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749122412&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28536

DO - 10.1556/OH.2009.28536

M3 - Article

VL - 150

SP - 65

EP - 71

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 2

ER -